Nephrology Dialysis Transplantation

NDT Advance Access originally published online on January 23, 2006
Nephrology Dialysis Transplantation 2006 21(4):1104-1108; doi:10.1093/ndt/gfk062

This Article Extract FREE Full Text (PDF) An erratum has been published All Versions of this Article: 21/4/1104    most recent gfk062v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (258) Request Permissions Disclaimer Google Scholar Articles by Grobner, T. Search for Related Content PubMed PubMed Citation Articles by Grobner, T. Social Bookmarking          What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

---

Interesting Case

Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Thomas Grobner

Department of Nephrology, General Hospital of Wiener Neustadt, A-2700 Wiener Neustadt, Austria

Correspondence and offprint requests to: Dr Thomas Grobner, 2. Interne Abteilung, Krankenhaus Wiener Neustadt, Corvinusring 3–5, A-2700 Wiener Neustadt, Austria. Email: dr.thomas.grobner{at}aon.at

Keywords: end stage renal disease; gadolinium–DTPA; metabolic acidosis; nephrogenic fibrosing dermopathy

	Introduction

Top Introduction Patients Results Discussion Conclusion References

 
Nephrogenic fibrosing dermopathy (NFD) is an acquired, idiopathic disorder that is observed in patients with renal disease. Most patients with NFD have undergone dialysis for renal failure [1,2]. It tends to affect mostly the middle-aged. An association of NFD with coagulation abnormalities, recent vascular surgery or intervention (e.g. shunt/fistula and angioplasty), and presence of antiphospholipid antibodies has been discussed by several authors thus far [1,3], but the origin of the disease is still unknown. A more widespread variant of this fibrosing skin disease with involvement of other organs (e.g. lungs, liver, muscles and the heart) is described as nephrogenic systemic fibrosis (NSF) by Leboit [4], Ting et al. [5] and Daram et al. [6].

NFD is characterized clinically by thickening, induration and hardening of the skin. Distinct nodules also can be seen. The (distal) extremities are the most common area of involvement, followed by the trunk, and the face is almost never involved [1]. The diagnosis of NFD is confirmed in a skin biopsy by specific histopathologic features, namely thickened collagen bundles with surrounding clefts, mucin deposition and a proliferation of fibroblasts and elastic fibers. Signs of inflammation are absent, which makes this disorder a distinct entity [1,7].

In this report, nine end stage renal disease patients undergoing magnetic resonance (MR) angiography are presented, in five of whom skin changes of nephrogenic fibrosing dermatopathy became apparent about 2–4 weeks after the administration of gadolinium (Gd)-containing contrast agent for MR. Patients with and without NFD were compared for possible risk factors to develop this skin disease. Gd is thought to be safe as a contrast agent in renal failure. This case series however, demonstrates that Gd–DTPA possibly plays a triggering role in the development of NFD under certain circumstances.

	Patients

Top Introduction Patients Results Discussion Conclusion References

 
Nine end stage renal disease patients of our dialysis unit underwent MR angiography using Gd–DTPA as contrast media over a period of approximately 2 years (mean age: 58±10.3 years; mean time on dialysis: 30.5±16.1 months). Among these patients, five were observed, all of whom developed thickening and induration of the skin, starting on the lower extremities and eventually spreading to the trunk and upper extremities (Table 1).

View this table: [in this window] [in a new window]   Table 1. Characteristics of affected patients

 
The skin was shiny and hard to the touch and the patients suffered from concomitant pain in affected areas. Conjunctival erythaema and yellowish scleral plaques could also be observed in these patients. Histologic examination of the skin biopsies taken revealed the picture of NFD. A characteristic example is given in Figures 1 and 2A,B.

View larger version (152K): [in this window] [in a new window]   Fig. 1. Biopsy specimen of the skin of the right lower leg of patient 1. The thickened dermis demonstrates plumped collagen bundles with surrounding clefts, spindle cellproliferation. Interstitial mucin deposition is frequently present.

 

View larger version (122K): [in this window] [in a new window]   Fig. 2. Magnification of skin biopsy shown in figure 1. (A) Fibroblasts and plumped collagen bundles with surrounding clefts. (B) Increased interstitial mucin deposition. (Figures 1 and 2A,B: Haematoxylin and eosin stain).

 

	Results

Top Introduction Patients Results Discussion Conclusion References

 
All affected patients underwent MR examination with the use of Gd–DTPA 2–4 weeks prior to development of the skin abnormalities.

Until the development of the skin changes, their course was uneventful. The laboratory examination including antinuclear antibodies, antineutrophil cytoplasmatic antibodies, anti phospholipid antibodies, circulating immuncomplexes, anti glomerular basal membrane antibodies and complement factors C3, C4 were negative or showed normal findings. In one patient a pathological value regarding protein C and factor VIII was detected (Table 2). The mean time on dialysis of the five affected patients amounted to 36±16.5 months.

View this table: [in this window] [in a new window]   Table 2. Further characteristics of NFD – patients

 
Data of the four patients not affected by skin disease is given in Table 3. Their mean time on dialysis amounted to 23.75±12.5 months. No other differences were found with respect to age, sex, medication, underlying renal disease, dialysis modalities and comorbidities; only the mean time on dialysis seemed to be longer in affected patients.

View this table: [in this window] [in a new window]   Table 3. Characteristics of unaffected patients

 
Strikingly, all affected patients had metabolic acidosis, while all unaffected patients showed normal findings regarding pH- value and actual bicarbonate at time of MR angiography. The mean age of the affected five patients was 57.2±10.7 years and their mean time on dialysis amounted to 36±16.5 months. The mean time of observation with the disease was 9.2±4.7 months. The mean age of the four patients without development of the skin changes was 59±9.7 years. Their mean time on dialysis amounted to 23.75±12.5 months. Comparing the two groups of patients, the mean time on dialysis was longer in affected patients. Age, sex, underlying renal disease, drug therapy including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, dialysis modalities and comorbid conditions showed no correlation with the development of the skin disease.

However, the mean pH-value of the affected patients amounted to 7.29±0.04 and the mean actual bicarbonate value was 19.5±1.7 mmol/l. The mean pH-value of the four unaffected patients was 7.39±0.01 and the mean value of actual bicarbonate was 22.95±0.58 mmol/l.

	Discussion

Top Introduction Patients Results Discussion Conclusion References

 
All haemodialysis patients with NFD had undergone MR angiography within 2–4 weeks before the onset of the skin changes. Gd–DTPA was administered intravenously as a contrast agent. A literature survey revealed no reports on comparable findings in Gd exposed patients.

Gd–DTPA introduced in 1988 is the first paramagnetic contrast agent approved for clinical use in MR imaging. The frequency of adverse reactions (headache, nausea, pain and sensation of cold at the site of injection, taste perversion, dizziness, vasodilation and reduced threshold for seizures) is low. Gd-containing contrast agents are widely used as contrast media and are thought to be safe, even in patients with impaired renal function. The Gd–DTPA is a small complex and diffuses easily through the pores of the vessels. Although Gd-containing contrast agents are rapidly cleared with a half-life of about 2 h in patients with normal renal function, in chronic renal failure half-life is prolonged and may exceed 30–120 h. Lack of immediate adequate dialysis after MR angiography significantly prolongs Gd clearance [8]. Possible side effects occur due to dissociation of the Gd–ligand complex into metal ion and ligand. This process is facilitated both by endogenous metals like zinc, copper, and iron, further calcium, and endogenous acids, destabilizing the complex and leading to its dissociation [9]. In renal failure the combination of metabolic acidosis and the absence of adequate clearance of Gd-containing agent is present [10].

Free Gd ion solubility is poor and can form precipitates of salts with anions like phosphate [10] – that is usually elevated in dialysis population – and with carbonate or hydroxyl, which are deposited in the interstium of muscle, bone, liver and skin and other organs and may cause a sparse initial infiltration of inflammatory cells with expression of TGF-beta.

MR imaging with use of gadolinium is an examination that is not done very often in the entire cohort of dialysis patients. During the 2 years of observation, nine patients were exposed to Gd. Comparing the two groups of patients, the only differences observed were that the mean time on dialysis was longer in affected patients and that they were acidotic at the time of using Gd.

NFD is a rare, relatively newly described disease, and its exact pathogenesis is not well understood. Because of the association with tissue injury, including vascular tissue injury (e.g. vascular surgery) and thrombotic episodes in some cases of NFD, endothelial damage with elevated levels of cytokines may be partially responsible for the development of NFD. Data from the registry suggests that thrombotic complications could trigger the skin changes [3].

It has been suggested that the spindle cells involved in NFD/NSF are circulating fibrocytes (CD 34/procollagen I positive cells) that are normally present in the blood and are involved in wound repair and tissue remodelling. These circulating fibrocytes would be aberrantly recruited to the dermis in the absence of overt tissue injury [3,12,13].

Mackay–Wiggan et al. [14] described elevated anticardiolipin antibodies in some of their affected patients. Not all our patients underwent surgery, or had thrombotic episodes in a close time relation to the development of the skin changes, and have not shown elevated anticardiolipin antibodies. Another hypothesis regarding angiotensin-converting enzyme inhibitors as a trigger [15] could not be confirmed in our dialysis unit.

Other investigators observed the expression of transforming growth factor beta 1, which is a potent stimulus for the production of collagen I by some cell types and mediates interstitial fibrosis [11].

NFD was unknown before March 1997 and some authors suggest that the sudden occurrence of the disease in the last 8 years makes it likely that a new agent or technique of examination causes NFD/NSF [1,3,4,6,16].

So far more than 170 cases have been identified worldwide. There seems to be no gender predilection.

Typical is the unique histopathology of NFD that includes thickened collagen bundles with surrounding clefts, increased dermal mucin deposition, proliferation of dendritic cells and increased elastic fibers [1]. Multinucleated cells positive for CD 68 and XIIIa and an increased expression of TGF-beta1 have also been observed [1,11]. Some of the clinical manifestations of NFD are similar to other fibrosing disorders like morphea, systemic sclerosis, eosinophilic fasciitis, ß2-microglobulin amyloidosis, scleromyxedema, fibroblastic rheumatism, Morbus Köhlmeier–Degos, necrobiosis lipoidica and eosiniphilia–myalgia syndrome.

There is no effective treatment for NFD. Physical therapy should be started to improve the range of motion of contracted joints. Various medical therapies including topical and systemic steroids, immunosuppressive therapy have been ineffective. Plasmapheresis have shown some benefit in some patients, and recently improvement was reported after photopheresis in three patients [17,18]. Thalidomide has also shown some improvement in three patients [19]. The influence of erythropoietin dosage has also been investigated. It was suggested that decreasing the erythropoietin dose might improve NFD in some patients because recombinant erythropoietin has potential fibrogenic properties [4]. Significant improvement was seen in several patients with a return to normal kidney function, either spontaneously or as a result of renal transplantation [3].

In our center the course of the patients was different. Patient 1 improved as a result of renal transplantation, patient 2 died a few weeks later due to myocardial infarction, patient 3 refused any additional therapy and is waiting for renal transplantation. Patients 4 and 5 are also awaiting renal transplantation. As photopheresis was under investigation at the time of diagnosis, we decided to treat with pentoxyfyllin, a substance with anti- tumour necrosis factor activity that has shown some benefits in other fibrotic disorders [20,21]. A treatment with 1200 mg pentoxifyllin orally per day was established and the extension of skin changes of patient 4, who was in a later phase of the disease, seemed to slow or arrest. Patient 5 was treated in an early phase of the disease and there a stabilization and a slight reversal of the process has been observed. Regarding pentoxifyllin, it is unclear what contribution vasodilation with possible ameliorating renal perfusion and antifibrotic activity had in the clinical stabilization of the disease. Controlled studies of therapy for NFD must be done.

	Conclusion

Top Introduction Patients Results Discussion Conclusion References

 
In end stage renal disease patients undergoing magnetic resonance imaging with the use of Gd-DTPA, attention should be drawn to the correction of metabolic acidosis, as acidosis and Gd-DTPA could play a triggering role for the development of nephrogenic fibrosing dermopathy (NFD).

	Acknowledgments

 
The author is grateful to the pathologist Dr. Eva Markis from the General Hospital of Wiener Neustadt for the pathology examinations of skin biopsies and Figures 1 and 2.

Conflict of interest statement. I do not declare any conflict of interest.

	References

Top Introduction Patients Results Discussion Conclusion References

 

1. Cowper SE, Su L, Robin H, Bhawan J, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383–393[CrossRef][Web of Science][Medline]
2. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med2003; 114: 563–572[CrossRef][Web of Science][Medline]
3. Cowper SE. Nephrogenic fibrosing dermopathy: the first six Years. Curr Opin Rheumatol 2003; 15: 785–790[CrossRef][Web of Science][Medline]
4. Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003; 139: 928–930[Free Full Text]
5. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903–906[Abstract/Free Full Text]
6. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754–759[CrossRef][Web of Science][Medline]
7. McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol 2002; 41: 364–367[CrossRef][Web of Science][Medline]
8. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491–502[CrossRef][Web of Science][Medline]
9. Mann JS. Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 1993; 17: S19–S23[Medline]
10. Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilizing properties of the gadolinium – DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003; 18: 884–887[Abstract/Free Full Text]
11. Jimenez SA, Artlett CM, Sandorfi N et al. Nephrogenic fibrosing dermopathy: study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660–2666[CrossRef][Web of Science][Medline]
12. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, Motive Unclear. [Letter]. Am J Dermatopathol 2003; 25: 358[CrossRef][Web of Science][Medline]
13. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen – secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36: 598–606[CrossRef][Web of Science][Medline]
14. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). Am Acad Dermatol 2003; 48: 55–60[CrossRef][Web of Science][Medline]
15. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? [Letter]. Arch Dermatol 2004; 140: 1401[Free Full Text]
16. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763–765[CrossRef][Medline]
17. Baron PW, Cantos K, Hillebrand DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25: 204–209[CrossRef][Web of Science][Medline]
18. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporal photopheresis. Br J Dermatol 2005; 152: 531–536[CrossRef][Web of Science][Medline]
19. Moschella SL, Kay J, Mackool BT, Liu V. Case 35–2004. A 68-year-old man with end stage renal disease and thickening of the skin. N Engl J Med 2004; 351: 2219–2227[Free Full Text]
20. Vicktor C., Schultz-Ehrenburg U. Papulosis maligna atrophicans (Köhlmeier – Degos) Hautarzt 2001; 52; 734–737[Medline]
21. Littler CM, Tschen EH. Pentoxifylline for necrobiosis lipoidica diabeticorum. J Am Acad Dermatol 1987; 17: 314–316[Medline]

Received for publication: 12. 6.05
Accepted in revised form: 21.12.05

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				M. F. Morris, Y. Zhang, H. Zhang, J. C. Prowda, D. N. Silvers, R. A. Fawwaz, and M. R. Prince Features of Nephrogenic Systemic Fibrosis on Radiology Examinations Am. J. Roentgenol., July 1, 2009; 193(1): 61 - 69. [Abstract] [Full Text] [PDF]

				R. P. Lim, P. Storey, I. P. Atanasova, J. Xu, E. M. Hecht, J. S. Babb, D. R. Stoffel, H. Chang, K. McGorty, Q. Chen, et al. Three-dimensional Electrocardiographically Gated Variable Flip Angle FSE Imaging for MR Angiography of the Hands at 3.0 T: Initial Experience Radiology, June 30, 2009; (2009) 2531090290. [Abstract] [Full Text]

				H. Jarvelainen, A. Sainio, M. Koulu, T. N. Wight, and R. Penttinen Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy Pharmacol. Rev., June 1, 2009; 61(2): 198 - 223. [Abstract] [Full Text] [PDF]

				M. D. Bridges, B. S. St. Amant, R. B. McNeil, J. G. Cernigliaro, J. P. Dwyer, and P. M. Fitzpatrick High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function Am. J. Roentgenol., June 1, 2009; 192(6): 1538 - 1543. [Abstract] [Full Text] [PDF]

				S. Kim, M. Jain, A. B. Harris, V. S. Lee, J. S. Babb, E. E. Sigmund, L. E. Rueff, and B. Taouli T1 Hyperintense Renal Lesions: Characterization with Diffusion-weighted MR Imaging versus Contrast-enhanced MR Imaging Radiology, June 1, 2009; 251(3): 796 - 807. [Abstract] [Full Text] [PDF]

				A. Kribben, O. Witzke, U. Hillen, J. Barkhausen, A. E. Daul, and R. Erbel Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1621 - 1628. [Abstract] [Full Text] [PDF]

				J. Gossner, M. R. Prince, H. Zhang, M. Morris, C. M. Magro, and R. L. DeLapaz Is Nephrogenic Systemic Fibrosis Linked to the Introduction of Contrast-enhanced MR Angiography? Radiology, May 1, 2009; 251(2): 612 - 613. [Full Text] [PDF]

				B. Taouli, R. K. Thakur, L. Mannelli, J. S. Babb, S. Kim, E. M. Hecht, V. S. Lee, and G. M. Israel Renal Lesions: Characterization with Diffusion-weighted Imaging versus Contrast-enhanced MR Imaging Radiology, May 1, 2009; 251(2): 398 - 407. [Abstract] [Full Text] [PDF]

				H. Steen, E. Giannitsis, C. Sommerer, U. Bahner, M. Brandl, C. Merbach, C. Merten, E. Ritz, H. A. Katus, M. Zeier, et al. Acute phase reaction to gadolinium-DTPA in dialysis patients Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1274 - 1277. [Abstract] [Full Text] [PDF]

				G. Roditi MRI contrast agent safety in renal impairment Clin Risk, March 1, 2009; 15(2): 47 - 53. [Full Text] [PDF]

				R. Agarwal, S. M. Brunelli, K. Williams, M. D. Mitchell, H. I. Feldman, and C. A. Umscheid Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis Nephrol. Dial. Transplant., March 1, 2009; 24(3): 856 - 863. [Abstract] [Full Text] [PDF]

				N. Bangsgaard, P. Marckmann, K. Rossen, and L. Skov Nephrogenic Systemic Fibrosis: Late Skin Manifestations Arch Dermatol, February 1, 2009; 145(2): 183 - 187. [Abstract] [Full Text] [PDF]

				H S SU, R M NAZARIAN, and J A SCOTT Appearance of nephrogenic fibrosing dermopathy on a bone scan Br. J. Radiol., February 1, 2009; 82(974): e35 - e36. [Abstract] [Full Text] [PDF]

				S. G. Silverman, J. R. Leyendecker, and E. S. Amis Jr What Is the Current Role of CT Urography and MR Urography in the Evaluation of the Urinary Tract? Radiology, February 1, 2009; 250(2): 309 - 323. [Abstract] [Full Text] [PDF]

				J. Perez-Rodriguez, S. Lai, B. D. Ehst, D. M. Fine, and D. A. Bluemke Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment--Report of 33 Cases Radiology, February 1, 2009; 250(2): 371 - 377. [Abstract] [Full Text] [PDF]

				M. A. Perazella Current Status of Gadolinium Toxicity in Patients with Kidney Disease Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 461 - 469. [Abstract] [Full Text] [PDF]

				R. J. Gibbons, P. A. Araoz, and E. E. Williamson The year in cardiac imaging. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 54 - 70. [Full Text] [PDF]

				K. Juluru, J. Vogel-Claussen, K. J. Macura, I. R. Kamel, A. Steever, and D. A. Bluemke Quality Initiatives * MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient Safety RadioGraphics, January 1, 2009; 29(1): 9 - 22. [Abstract] [Full Text] [PDF]

				K. De Wilde, P. Peeters, M. Praet, M. Petrovic, and R. Vanholder Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours NDT Plus, December 1, 2008; 1(6): 469 - 470. [Full Text] [PDF]

				C. D. Wiginton Implications of NSF-Active and NSF-Inert in Nephrogenic Systemic Fibrosis Am. J. Roentgenol., December 1, 2008; 191(6): 1864 - 1866. [Full Text] [PDF]

				J Kay Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii66 - iii69. [Abstract] [Full Text] [PDF]

				A. Chiribiri, S. Kelle, U. Kohler, L. F. Tops, B. Schnackenburg, R. Bonamini, J. J. Bax, E. Fleck, and E. Nagel Magnetic resonance cardiac vein imaging: relation to mitral valve annulus and left circumflex coronary artery. J. Am. Coll. Cardiol. Img., November 1, 2008; 1(6): 729 - 738. [Abstract] [Full Text] [PDF]

				R.P. Lim, M. Shapiro, E.Y. Wang, M. Law, J.S. Babb, L.E. Rueff, J.S. Jacob, S. Kim, R.H. Carson, T.P. Mulholland, et al. 3D Time-Resolved MR Angiography (MRA) of the Carotid Arteries with Time-Resolved Imaging with Stochastic Trajectories: Comparison with 3D Contrast-Enhanced Bolus-Chase MRA and 3D Time-Of-Flight MRA AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1847 - 1854. [Abstract] [Full Text] [PDF]

				S. Zelasko, M. Hollingshead, M. Castillo, and T.W. Bouldin CT and MR Imaging of Progressive Dural Involvement by Nephrogenic Systemic Fibrosis AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1880 - 1882. [Abstract] [Full Text] [PDF]

				J. C. Weinreb Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? Radiology, October 1, 2008; 249(1): 3 - 8. [Full Text] [PDF]

				R. A. Halvorsen Which Study When? Iodinated Contrast-enhanced CT Versus Gadolinium-enhanced MR Imaging Radiology, October 1, 2008; 249(1): 9 - 15. [Full Text] [PDF]

				S. G. Silverman, G. M. Israel, B. R. Herts, and J. P. Richie Management of the Incidental Renal Mass Radiology, October 1, 2008; 249(1): 16 - 31. [Abstract] [Full Text] [PDF]

				F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]

				P. M. Colletti Nephrogenic Systemic Fibrosis and Gadolinium: A Perfect Storm Am. J. Roentgenol., October 1, 2008; 191(4): 1150 - 1153. [Full Text] [PDF]

				R. Agid, R.A. Willinsky, S.-K. Lee, K.G. TerBrugge, and R.I. Farb Characterization of Aneurysm Remnants after Endovascular Treatment: Contrast-Enhanced MR Angiography versus Catheter Digital Subtraction Angiography AJNR Am. J. Neuroradiol., September 1, 2008; 29(8): 1570 - 1574. [Abstract] [Full Text] [PDF]

				M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman, J. Silberzweig, R. L. DeLapaz, H. J. Lee, C. M. Magro, and A. M. Valeri Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers Radiology, September 1, 2008; 248(3): 807 - 816. [Abstract] [Full Text] [PDF]

				R. Wertman, , BA, E. Altun, D. R. Martin, D. G. Mitchell, J. R. Leyendecker, R. B. O'Malley, D. J. Parsons, E. R. Fuller III, and R. C. Semelka Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities Radiology, September 1, 2008; 248(3): 799 - 806. [Abstract] [Full Text] [PDF]

				M E ABOU EL-GHAR, A A SHOKEIR, H F REFAIE, and T A EL-DIASTY MRI in patients with chronic obstructive uropathy and compromised renal function: a sole method for morphological and functional assessment Br. J. Radiol., August 1, 2008; 81(968): 624 - 629. [Abstract] [Full Text] [PDF]

				B. J. Schietinger, G. M. Brammer, H. Wang, J. M. Christopher, K. W. Kwon, A. J. Mangrum, J. M. Mangrum, and C. M. Kramer Patterns of late gadolinium enhancement in chronic hemodialysis patients. J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 450 - 456. [Abstract] [Full Text] [PDF]

				N. M. Rofsky Nephrogenic systemic fibrosis: considerations for the cardiologist. J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 457 - 459. [Full Text] [PDF]

				M. Miyazaki and V. S. Lee Nonenhanced MR Angiography Radiology, July 1, 2008; 248(1): 20 - 43. [Abstract] [Full Text] [PDF]

				J. A. Schroeder, C. Weingart, B. Coras, I. Hausser, S. Reinhold, M. Mack, V. Seybold, T. Vogt, B. Banas, F. Hofstaedter, et al. Ultrastructural Evidence of Dermal Gadolinium Deposits in a Patient with Nephrogenic Systemic Fibrosis and End-Stage Renal Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 968 - 975. [Abstract] [Full Text] [PDF]

				H. Ersoy and F. J. Rybicki MR Angiography of the Lower Extremities Am. J. Roentgenol., June 1, 2008; 190(6): 1675 - 1684. [Abstract] [Full Text] [PDF]

				R. F. Reilly Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term Hemodialysis Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 747 - 751. [Abstract] [Full Text] [PDF]

				M. A. Perazella How Should Nephrologists Approach Gadolinium-based Contrast Imaging in Patients with Kidney Disease? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 649 - 651. [Full Text] [PDF]

				G. Zaharchuk, A.J. Martin, and W.P. Dillon Noninvasive Imaging of Quantitative Cerebral Blood Flow Changes during 100% Oxygen Inhalation Using Arterial Spin-Labeling MR Imaging AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 663 - 667. [Abstract] [Full Text] [PDF]

				G. C. Kane, A. W. Stanson, D. Kalnicka, D. W. Rosenthal, C. U. Lee, S. C. Textor, and V. D. Garovic Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1233 - 1240. [Abstract] [Full Text] [PDF]

				C. D. Wiginton, B. Kelly, A. Oto, M. Jesse, P. Aristimuno, R. Ernst, and G. Chaljub Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue Am. J. Roentgenol., April 1, 2008; 190(4): 1060 - 1068. [Abstract] [Full Text] [PDF]

				L. P. Golding and J. M. Provenzale Nephrogenic Systemic Fibrosis: Possible Association with a Predisposing Infection Am. J. Roentgenol., April 1, 2008; 190(4): 1069 - 1075. [Abstract] [Full Text] [PDF]

				W. M. Shabana, R. H. Cohan, J. H. Ellis, H. K. Hussain, I. R. Francis, L. D. Su, S. K. Mukherji, and R. D. Swartz Nephrogenic Systemic Fibrosis: A Report of 29 Cases Am. J. Roentgenol., March 1, 2008; 190(3): 736 - 741. [Abstract] [Full Text] [PDF]

				J. Kay, H. Bazari, L. L. Avery, and A. F. Koreishi Case 6-2008 -- A 46-Year-Old Woman with Renal Failure and Stiffness of the Joints and Skin N. Engl. J. Med., February 21, 2008; 358(8): 827 - 838. [Full Text] [PDF]

				N. ISSA, E. D. POGGIO, R. A. FATICA, R. PATEL, P. M. RUGGIERI, and R. J. HEYKA Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 95 - 111. [Abstract] [Full Text] [PDF]

				J. R. Leyendecker, C. E. Barnes, and R. J. Zagoria MR Urography: Techniques and Clinical Applications RadioGraphics, January 1, 2008; 28(1): 23 - 46. [Abstract] [Full Text] [PDF]

				F. Stepansky, E. M. Hecht, R. Rivera, L. E. Hirsh, B. Taouli, M. Kaur, and V. S. Lee Dynamic MR Angiography of Upper Extremity Vascular Disease: Pictorial Review RadioGraphics, January 1, 2008; 28(1): e28 - e28. [Abstract] [Full Text]

				P. Marckmann, L. Skov, K. Rossen, J. G. Heaf, and H. S. Thomsen Case-control study of gadodiamide-related nephrogenic systemic fibrosis Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3174 - 3178. [Abstract] [Full Text] [PDF]

				J. L. Nortier and V. del Marmol Nephrogenic systemic fibrosis the need for a multidisciplinary approach Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3097 - 3101. [Full Text] [PDF]

				J. B. Othersen, J. C. Maize Jr., R. F. Woolson, and M. N. Budisavljevic Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3179 - 3185. [Abstract] [Full Text] [PDF]

				J.M. Morris and G.M. Miller Increased Signal in the Subarachnoid Space on Fluid-Attenuated Inversion Recovery Imaging Associated with the Clearance Dynamics of Gadolinium Chelate: A Potential Diagnostic Pitfall AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1964 - 1967. [Abstract] [Full Text] [PDF]

				M. Remy-Jardin, M. Pistolesi, L. R. Goodman, W. B. Gefter, A. Gottschalk, J. R. Mayo, and H. D. Sostman Management of Suspected Acute Pulmonary Embolism in the Era of CT Angiography: A Statement from the Fleischner Society Radiology, November 1, 2007; 245(2): 315 - 329. [Full Text] [PDF]

				C. Thakral and J. L. Abraham Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin J. Electron Microsc. (Tokyo), October 19, 2007; (2007) dfm020v1. [Abstract] [Full Text] [PDF]

				T. A. Collidge, P. C. Thomson, P. B. Mark, J. P. Traynor, A. G. Jardine, S. T. W. Morris, K. Simpson, and G. H. Roditi Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort Radiology, October 1, 2007; 245(1): 168 - 175. [Abstract] [Full Text] [PDF]

				S. Swaminathan and S. V. Shah New Insights into Nephrogenic Systemic Fibrosis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2636 - 2643. [Abstract] [Full Text] [PDF]

				G. Saab, A. Abu-Alfa, E. A. Sadowski, and A. Djamali Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology, September 1, 2007; 244(3): 930 - 932. [Full Text] [PDF]

				A. S Peak and A. Sheller Risk Factors for Developing Gadolinium-Induced Nephrogenic Systemic Fibrosis Ann. Pharmacother., September 1, 2007; 41(9): 1481 - 1485. [Abstract] [Full Text] [PDF]

				S. Swaminathan, T. D. Horn, D. Pellowski, S. Abul-Ezz, J. A. Bornhorst, S. Viswamitra, and S. V. Shah Nephrogenic Systemic Fibrosis, Gadolinium, and Iron Mobilization N. Engl. J. Med., August 16, 2007; 357(7): 720 - 722. [Full Text] [PDF]

				H. Richmond, J. Zwerner, Y. Kim, and D. Fiorentino Nephrogenic Systemic Fibrosis: Relationship to Gadolinium and Response to Photopheresis Arch Dermatol, August 1, 2007; 143(8): 1025 - 1030. [Abstract] [Full Text] [PDF]

				S. S. DeLoach and E. R. Mohler III Peripheral Arterial Disease: A Guide for Nephrologists Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 839 - 846. [Abstract] [Full Text] [PDF]

				P. C Thomson, T. A Collidge, P. B Mark, and J. P Traynor Gadolinium contrast may be risky in kidney disease BMJ, June 30, 2007; 334(7608): 1335 - 1336. [Full Text] [PDF]

				E. Kanal, A. J. Barkovich, C. Bell, J. P. Borgstede, W. G. Bradley Jr., J. W. Froelich, T. Gilk, J. R. Gimbel, J. Gosbee, E. Kuhni-Kaminski, et al. ACR Guidance Document for Safe MR Practices: 2007 Am. J. Roentgenol., June 1, 2007; 188(6): 1447 - 1474. [Full Text] [PDF]

				J. H. Maki, G. J. Wilson, W. B. Eubank, D. J. Glickerman, J. A. Millan, and R. M. Hoogeveen Navigator-Gated MR Angiography of the Renal Arteries: A Potential Screening Tool for Renal Artery Stenosis Am. J. Roentgenol., June 1, 2007; 188(6): W540 - W546. [Abstract] [Full Text] [PDF]

				H. S. Thomsen and S. K. Morcos Nephrogenic Systemic Fibrosis and Nonionic Linear Chelates Am. J. Roentgenol., June 1, 2007; 188(6): W580 - W580. [Full Text] [PDF]

				E. A. Sadowski, L. K. Bennett, M. R. Chan, A. L. Wentland, A. L. Garrett, R. W. Garrett, and A. Djamali Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation Radiology, April 1, 2007; 243(1): 148 - 157. [Abstract] [Full Text] [PDF]

				M. A. Perazella Nephrogenic Systemic Fibrosis, Kidney Disease, and Gadolinium: Is There a Link? Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 200 - 202. [Full Text] [PDF]

				P. Yerram, G. Saab, P. R. Karuparthi, M. R. Hayden, and R. Khanna Nephrogenic Systemic Fibrosis: A Mysterious Disease in Patients with Renal Failure--Role of Gadolinium-Based Contrast Media in Causation and the Beneficial Effect of Intravenous Sodium Thiosulfate Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 258 - 263. [Abstract] [Full Text] [PDF]

				P. H. Kuo, E. Kanal, A. K. Abu-Alfa, and S. E. Cowper Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis Radiology, March 1, 2007; 242(3): 647 - 649. [Full Text] [PDF]

				R. N. Hellman Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy Ann Intern Med, February 6, 2007; 146(3): 229 - 230. [Full Text] [PDF]

				I. M. Wahba, K. White, M. Meyer, and E. L. Simpson The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature Nephrol. Dial. Transplant., February 1, 2007; 22(2): 631 - 636. [Full Text] [PDF]

				D. R. Broome, M. S. Girguis, P. W. Baron, A. C. Cottrell, I. Kjellin, and G. A. Kirk Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned Am. J. Roentgenol., February 1, 2007; 188(2): 586 - 592. [Abstract] [Full Text] [PDF]

				S K Morcos Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol., February 1, 2007; 80(950): 73 - 76. [Full Text] [PDF]

				C. Stollberger and J. Finsterer Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy. Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3604 - 3604. [Full Text] [PDF]

				R. Nowack and P. Wachtler Scleroderma-like syndrome triggered by Gadolinium Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3344 - 3344. [Full Text] [PDF]

				Has the Cause of Nephrogenic Fibrosing Dermopathy Been Identified? Journal Watch Dermatology, September 8, 2006; 2006(908): 2 - 2. [Full Text]

				P. Marckmann, L. Skov, K. Rossen, A. Dupont, M. B. Damholt, J. G. Heaf, and H. S. Thomsen Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2359 - 2362. [Abstract] [Full Text] [PDF]

This Article Extract FREE Full Text (PDF) An erratum has been published All Versions of this Article: 21/4/1104    most recent gfk062v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (258) Request Permissions Disclaimer Google Scholar Articles by Grobner, T. Search for Related Content PubMed PubMed Citation Articles by Grobner, T. Social Bookmarking          What's this?

Online ISSN 1460-2385 - Print ISSN 0931-0509

Copyright © 2009 European Renal Association - European Dialysis and Transplant Assoc

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics